DrugPatentWatch Database Preview
Details for Patent: 8,633,309
Which drugs does patent 8,633,309 protect, and when does it expire?
Patent 8,633,309 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in four NDAs.
This patent has one hundred and forty patent family members in thirty-six countries.
This patent has one hundred and forty patent family members in thirty-six countries.
Summary for Patent: 8,633,309
| Title: | Nucleoside phosphoramidates |
| Abstract: | Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. |
| Inventor(s): | Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 13/738,425 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 8,633,309
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | FOR THE TREATMENT OF HEPATITIS C | ➤ Sign Up | ||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | TABLET;ORAL | 205834-001 | Oct 10, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | FOR THE TREATMENT OF HEPATITIS C | ➤ Sign Up | ||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | TABLET;ORAL | 204671-001 | Dec 6, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | FOR THE TREATMENT OF HEPATITIS C | ➤ Sign Up | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,633,309
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,637,512 | Nucleoside phosphoramidates | ➤ Sign Up |
| 9,206,217 | Nucleoside phosphoramidates | ➤ Sign Up |
| 8,629,263 | Nucleoside phosphoramidates | ➤ Sign Up |
| 8,642,756 | Nucleoside phosphoramidates | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 8,633,309
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 3515 | ➤ Sign Up | |||
| Argentina | 080819 | ➤ Sign Up | |||
| Argentina | 080870 | ➤ Sign Up | |||
| Argentina | 081813 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
